Literature DB >> 7262175

Pharmacokinetics of prednisolone in normal and asthmatic subjects in relation to dose.

W A McAllister, C R Winfield, J V Collins.   

Abstract

The pharmacokinetics of prednisolone have been studied in asthmatic patients following intravenous injection at three different doses and in normal volunteers at five oral doses. Plasma prednisolone concentrations were measured by radioimmunoassay. With increasing dose there is an increase in the apparent volume of distribution, plasma clearance and half life. The relationship between area under the plasma concentration time curve, maximum concentration and dose is linear but the regression lines do not pass through the origin. These findings following oral and intravenous administration confirm that prednisolone shows non-linear kinetics.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7262175     DOI: 10.1007/BF00607151

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  A radioimmunoassay method for prednisolone: comparison with the competitive protein binding method.

Authors:  J Chakraborty; J English; V Marks; M C Dumasia; D J Chapman
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

2.  Dose-dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J C Loo; I J McGilveray; N Jordan; J Moffat; R Brien
Journal:  J Pharm Pharmacol       Date:  1978-11       Impact factor: 3.765

3.  Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone.

Authors:  R G Henderson; T Wheatley; J English; J Chakraborty; V Marks
Journal:  Br Med J       Date:  1979-06-09

4.  Dose-dependent prednisolone kinetics.

Authors:  A Tanner; F Bochner; J Caffin; J Halliday; L Powell
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

5.  Prednisolone pharmacokinetics in relation to dose.

Authors:  J Q Rose; W J Jusko; J A Nickelsen; O C Green
Journal:  J Pediatr       Date:  1979-06       Impact factor: 4.406

6.  Oral prednisone for chronic active liver disease: dose responses and bioavailability studies.

Authors:  M Uribe; S W Schalm; W H Summerskill; V L Go
Journal:  Gut       Date:  1978-12       Impact factor: 23.059

7.  Dose dependent pharmacokinetics of prednisolone.

Authors:  M E Pickup; J R Lowe; P A Leatham; V M Rhind; V Wright; W W Downie
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

8.  Serum protein binding of prednisolone in four species.

Authors:  M L Rocci; N F Johnson; W J Jusko
Journal:  J Pharm Sci       Date:  1980-08       Impact factor: 3.534

  8 in total
  5 in total

1.  Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.

Authors:  Georgia Charkoftaki; Aristides Dokoumetzidis; Georgia Valsami; Panos Macheras
Journal:  Pharm Res       Date:  2012-07-04       Impact factor: 4.200

2.  Alterations in prednisolone disposition as a result of time of administration, gender and dose.

Authors:  P J Meffin; P M Brooks; B C Sallustio
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

3.  Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man.

Authors:  S Edsbäcker; K E Andersson; A Ryrfeldt
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Can oral corticosteroids reduce the severity or duration of an acute cough, and the associated National Health Service and societal costs, in adults presenting to primary care? Study protocol for a randomised controlled trial.

Authors:  Harriet E Downing; Fran Carroll; Sara T Brookes; Sandra Hollinghurst; David Timmins; Elizabeth Orton; Kay Wang; Denise Kendrick; Paul Little; Mike V Moore; Anthony Harnden; Matthew Thompson; Margaret T May; Alastair D Hay
Journal:  Trials       Date:  2015-03-07       Impact factor: 2.279

5.  Oral corticosteroids for post-infectious cough in adults: study protocol for a double-blind randomized placebo-controlled trial in Swiss family practices (OSPIC trial).

Authors:  Christoph Merlo; Stefan Essig; D Oana Brancati-Badarau; Jörg Daniel Leuppi; Benjamin Speich; Tobias E Erlanger; Lars G Hemkens; Andreas Zeller
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.